WHO ICTRP trial
A clinical trial of HAIC plus sintilimab and bevacizumab as treatment for…
ChiCTR2300068116 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300068116 |
|---|---|
| Public title | A clinical trial of HAIC plus sintilimab and bevacizumab as treatment for patients with advanced hepatocellular carcinoma |
| Scientific title | A clinical trial of HAIC plus sintilimab and bevacizumab as treatment for patients with advanced hepatocellular carcinoma |
| Primary sponsor | Eastern Hepatobiliary Surgery Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | hepatocellular carcinoma |
| Interventions | untreated patients with advanced hepatocellular carcinoma:HIAC plus sintilimab and bevacizumab |
| Registration date | Feb 7, 2023 |
| Target size | untreated patients with advanced hepatocellular carcinoma:46 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: